Last updated on November 2019

(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285) A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor in Patients With Advanced Systemic Mastocytosis


Find a site near you

Start Over

Stanford Cancer Institute

Stanford, CA United States
  Connect »

Mays Cancer Center

San Antonio, TX United States
  Connect »

Huntsman Cancer Institute

Salt Lake City, UT United States
  Connect »